Astrana Health (ASTH) has been trading with mixed momentum recently, with a gain over the past month alongside weaker returns over the past 3 months and 1 year. This has prompted some investors to reassess how its fundamentals line up.

At a share price of $27.12, Astrana Health’s 21.61% 30 day share price return sits against a weaker 1 year total shareholder return of 13.47% and a 3 year total shareholder return of 21.44%. This suggests recent momentum after a softer multi year experience.

If Astrana Health has you looking more broadly across the sector, it could be a good time to scan other healthcare stocks that may fit your watchlist next.

With Astrana Health posting a 30 day gain alongside weaker 1 year and 3 year returns, and trading below some valuation estimates, you have to ask: is this a genuine entry point, or is the market already pricing in future growth?

Most Popular Narrative: 32.6% Undervalued

With Astrana Health closing at $27.12 against a narrative fair value of $40.25, the story centers on whether future execution can bridge that gap.

Long-term tailwinds from regulatory and payer shifts toward alternative payment models and value-based healthcare are expanding the addressable market and favor operators with mature, risk-bearing platforms like Astrana. This sets the stage for durable revenue and profit growth as national healthcare expenditure rises. The ability to consistently deliver industry-leading medical cost trend control and build trusted partnerships with payers differentiates Astrana from competitors and may support higher contract renewal rates, lower member churn, and net margin resilience, including during volatile or cost-constrained healthcare environments.

Curious what kind of revenue climb, margin change, and future earnings multiple are implied by that fair value gap, and how much contract risk is assumed? The full narrative lays out those moving parts in detail.

Result: Fair Value of $40.25 (UNDERVALUED)

However, you also need to weigh the risk that heavy reliance on Medicare and Medicaid, along with complex full risk contract conversions, could disrupt this fair value story.

Another View: Earnings Multiple Sends A Very Different Signal

So far the story points to Astrana Health trading below some fair value estimates, but the current P/E of 142.6x tells a different story. That is far above the US Healthcare industry at 23.1x, the peer average at 49.3x, and even the fair ratio of 26.1x.

In plain terms, the share price currently embeds very rich earnings expectations compared with both peers and where the fair ratio suggests the P/E could move toward over time. The question is whether the future earnings delivery you expect really justifies paying this kind of premium today.

Build Your Own Astrana Health Narrative

If you see the story differently or simply prefer to test the assumptions yourself, you can build a complete Astrana Health view in minutes by starting with Do it your way.

A great starting point for your Astrana Health research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If you stop here, you only see one piece of the puzzle, so widen your opportunity set now by scanning targeted stock ideas that match different goals and risk profiles.

• Target potential value upside by screening for these 886 undervalued stocks based on cash flows that may trade on more modest expectations than the broader market.
• Tap into growth themes at the frontier of tech with these 25 AI penny stocks that are tied to artificial intelligence adoption across sectors.
• Build a steadier income stream by focusing on these 13 dividend stocks with yields > 3% that prioritise returning cash to shareholders through regular payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.